Skip to main content
NCBI home page
Postgraduate Medical Journal logoLink to Postgraduate Medical Journal
. 1993 Sep;69(815):735–738. doi: 10.1136/pgmj.69.815.735

Effects of octreotide on circulating islet B cell products in endogenous hyperinsulinism.

A J Krentz 1, J Pace 1, W Somerville 1, P M Clark 1, M Nattrass 1
PMCID: PMC2399757  PMID: 8255845

Abstract

The role of somatostatin analogues in the medical management of insulinomas is unclear. We describe an elderly patient with clinical and biochemical features of endogenous hyperinsulinism attributable to a benign islet B cell disorder whose incapacitating neuroglycopaenic symptoms responded dramatically to octreotide 50 micrograms subcutaneously at 2200 h each night. Octreotide suppressed inappropriate plasma concentrations of insulin thereby preventing fasting hypoglycaemia. Fasting concentrations of proinsulin, and 32-33 split proinsulin, as determined by two-site monoclonal antibody-based immunoradiometric assays, were also suppressed by octreotide.

Full text

PDF
735

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Battershill P. E., Clissold S. P. Octreotide. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in conditions associated with excessive peptide secretion. Drugs. 1989 Nov;38(5):658–702. doi: 10.2165/00003495-198938050-00002. [DOI] [PubMed] [Google Scholar]
  2. Boden G., Ryan I. G., Shuman C. R. Ineffectiveness of SMS 201-995 in severe hyperinsulinemia. Diabetes Care. 1988 Sep;11(8):664–668. doi: 10.2337/diacare.11.8.664. [DOI] [PubMed] [Google Scholar]
  3. Cohen R. M., Given B. D., Licinio-Paixao J., Provow S. A., Rue P. A., Frank B. H., Root M. A., Polonsky K. S., Tager H. S., Rubenstein A. H. Proinsulin radioimmunoassay in the evaluation of insulinomas and familial hyperproinsulinemia. Metabolism. 1986 Dec;35(12):1137–1146. doi: 10.1016/0026-0495(86)90027-2. [DOI] [PubMed] [Google Scholar]
  4. Fajans S. S., Vinik A. I. Insulin-producing islet cell tumors. Endocrinol Metab Clin North Am. 1989 Mar;18(1):45–74. [PubMed] [Google Scholar]
  5. Glaser B., Landau H., Smilovici A., Nesher R. Persistent hyperinsulinaemic hypoglycaemia of infancy: long-term treatment with the somatostatin analogue Sandostatin. Clin Endocrinol (Oxf) 1989 Jul;31(1):71–80. doi: 10.1111/j.1365-2265.1989.tb00455.x. [DOI] [PubMed] [Google Scholar]
  6. Gray I. P., Siddle K., Docherty K., Frank B. H., Hales C. N. Proinsulin in human serum: problems in measurement and interpretation. Clin Endocrinol (Oxf) 1984 Jul;21(1):43–47. doi: 10.1111/j.1365-2265.1984.tb00134.x. [DOI] [PubMed] [Google Scholar]
  7. HALES C. N., RANDLE P. J. Immunoassay of insulin with insulin-antibody precipitate. Biochem J. 1963 Jul;88:137–146. doi: 10.1042/bj0880137. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Harrison T. S., Child C. G., Fry W. J., Floyd J. C., Jr, Fajans S. S. Current surgical management of functioning islet cell tumors of the pancreas. Ann Surg. 1973 Oct;178(4):485–495. doi: 10.1097/00000658-197310000-00011. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Katz M. D., Erstad B. L. Octreotide, a new somatostatin analogue. Clin Pharm. 1989 Apr;8(4):255–273. [PubMed] [Google Scholar]
  10. Longnecker S. M. Somatostatin and octreotide: literature review and description of therapeutic activity in pancreatic neoplasia. Drug Intell Clin Pharm. 1988 Feb;22(2):99–106. doi: 10.1177/106002808802200201. [DOI] [PubMed] [Google Scholar]
  11. Peavy D. E., Brunner M. R., Duckworth W. C., Hooker C. S., Frank B. H. Receptor binding and biological potency of several split forms (conversion intermediates) of human proinsulin. Studies in cultured IM-9 lymphocytes and in vivo and in vitro in rats. J Biol Chem. 1985 Nov 15;260(26):13989–13994. [PubMed] [Google Scholar]
  12. Rosenberg J. M. Octreotide: a synthetic analog of somatostatin. Drug Intell Clin Pharm. 1988 Oct;22(10):748–754. doi: 10.1177/106002808802201001. [DOI] [PubMed] [Google Scholar]
  13. Sherman B. M., Pek S., Fajans S. S., Floyd J. C., Jr, Conn J. W. Plasma proinsulin in patients with functioning pancreatic islet cell tumors. J Clin Endocrinol Metab. 1972 Aug;35(2):271–280. doi: 10.1210/jcem-35-2-271. [DOI] [PubMed] [Google Scholar]
  14. Sobey W. J., Beer S. F., Carrington C. A., Clark P. M., Frank B. H., Gray I. P., Luzio S. D., Owens D. R., Schneider A. E., Siddle K. Sensitive and specific two-site immunoradiometric assays for human insulin, proinsulin, 65-66 split and 32-33 split proinsulins. Biochem J. 1989 Jun 1;260(2):535–541. doi: 10.1042/bj2600535. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Stefanini P., Carboni M., Patrassi N., Basoli A. Beta-islet cell tumors of the pancreas: results of a study on 1,067 cases. Surgery. 1974 Apr;75(4):597–609. [PubMed] [Google Scholar]
  16. Stehouwer C. D., Lems W. F., Fischer H. R., Hackeng W. H., Naafs M. A. Aggravation of hypoglycemia in insulinoma patients by the long-acting somatostatin analogue octreotide (Sandostatin). Acta Endocrinol (Copenh) 1989 Jul;121(1):34–40. doi: 10.1530/acta.0.1210034. [DOI] [PubMed] [Google Scholar]
  17. Williams D. R., Byrne C., Clark P. M., Cox L., Day N. E., Rayman G., Wang T., Hales C. N. Raised proinsulin concentration as early indicator of beta cell dysfunction. BMJ. 1991 Jul 13;303(6794):95–96. doi: 10.1136/bmj.303.6794.95-a. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Postgraduate Medical Journal are provided here courtesy of BMJ Publishing Group

RESOURCES